BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim G, Eom YW, Baik SK, Shin Y, Lim YL, Kim MY, Kwon SO, Chang SJ. Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis. J Korean Med Sci. 2015;30:1405-1415. [PMID: 26425036 DOI: 10.3346/jkms.2015.30.10.1405] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Kang SH, Kim MY, Baik SK. Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon. Hepatol Int 2018;12:112-21. [DOI: 10.1007/s12072-017-9806-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
2 Wang M, Yang G, Jiang X, Lu D, Mei H, Chen B. Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α (PGC-1α) Regulates the Expression of B-Cell Lymphoma/Leukemia-2 (Bcl-2) and Promotes the Survival of Mesenchymal Stem Cells (MSCs) via PGC-1α/ERRα Interaction in the Absence of Serum, Hypoxia, and High Glucose Conditions. Med Sci Monit 2017;23:3451-60. [PMID: 28711948 DOI: 10.12659/msm.902183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fathy M, Okabe M, Saad Eldien HM, Yoshida T. AT-MSCs Antifibrotic Activity is Improved by Eugenol through Modulation of TGF-β/Smad Signaling Pathway in Rats. Molecules 2020;25:E348. [PMID: 31952158 DOI: 10.3390/molecules25020348] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Zhao L, Chen S, Shi X, Cao H, Li L. A pooled analysis of mesenchymal stem cell-based therapy for liver disease. Stem Cell Res Ther. 2018;9:72. [PMID: 29562935 DOI: 10.1186/s13287-018-0816-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]
5 Than NN, Tomlinson CL, Haldar D, King AL, Moore D, Newsome PN. Clinical effectiveness of cell therapies in patients with chronic liver disease and acute-on-chronic liver failure: a systematic review protocol. Syst Rev. 2016;5:100. [PMID: 27301957 DOI: 10.1186/s13643-016-0277-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
6 Ng NN, Thakor AS. Locoregional delivery of stem cell-based therapies. Sci Transl Med 2020;12:eaba4564. [PMID: 32522806 DOI: 10.1126/scitranslmed.aba4564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rostami T, Maleki N, Kasaeian A, Nikbakht M, Kiumarsi A, Asadollah Mousavi S, Ghavamzadeh A. Co-transplantation of bone marrow-derived mesenchymal stem cells with hematopoietic stem cells does not improve transplantation outcome in class III beta-thalassemia major: A prospective cohort study with long-term follow-up. Pediatr Transplant 2021;25:e13905. [PMID: 33179398 DOI: 10.1111/petr.13905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Lim YL, Eom YW, Park SJ, Hong T, Kang SH, Baik SK, Park KS, Kim MY. Bone Marrow-Derived Mesenchymal Stem Cells Isolated from Patients with Cirrhosis and Healthy Volunteers Show Comparable Characteristics. Int J Stem Cells 2020;13:394-403. [PMID: 32840228 DOI: 10.15283/ijsc20072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Al-Dhamin Z, Liu LD, Li DD, Zhang SY, Dong SM, Nan YM. Therapeutic efficiency of bone marrow-derived mesenchymal stem cells for liver fibrosis: A systematic review of in vivo studies. World J Gastroenterol 2020; 26(47): 7444-7469 [PMID: 33384547 DOI: 10.3748/wjg.v26.i47.7444] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Marycz K, Szłapka-Kosarzewska J, Geburek F, Kornicka-Garbowska K. Systemic Administration of Rejuvenated Adipose-Derived Mesenchymal Stem Cells Improves Liver Metabolism in Equine Metabolic Syndrome (EMS)- New Approach in Veterinary Regenerative Medicine. Stem Cell Rev Rep 2019;15:842-50. [PMID: 31620992 DOI: 10.1007/s12015-019-09913-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
11 Kang HT, Jun DW, Jang K, Hoh J, Lee JS, Saeed WK, Chae YJ, Lee JH. Effect of Stem Cell Treatment on Acute Liver Failure Model Using Scaffold. Dig Dis Sci 2019;64:781-91. [DOI: 10.1007/s10620-018-5363-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Shim KY, Eom YW, Kim MY, Kang SH, Baik SK. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. Korean J Intern Med. 2018;33:453-461. [PMID: 29462546 DOI: 10.3904/kjim.2017.317] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
13 Wang P, Petrella F, Nicosia L, Bellomi M, Rizzo S. Molecular Imaging of Stem Cell Transplantation for Liver Diseases: Monitoring, Clinical Translation, and Theranostics. Stem Cells Int. 2016;2016:4058656. [PMID: 28070195 DOI: 10.1155/2016/4058656] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mardpour S, Ghanian MH, Sadeghi-Abandansari H, Mardpour S, Nazari A, Shekari F, Baharvand H. Hydrogel-Mediated Sustained Systemic Delivery of Mesenchymal Stem Cell-Derived Extracellular Vesicles Improves Hepatic Regeneration in Chronic Liver Failure. ACS Appl Mater Interfaces. 2019;11:37421-37433. [PMID: 31525863 DOI: 10.1021/acsami.9b10126] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
15 Kim G, Kim J, Lim YL, Kim MY, Baik SK. Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatol Int. 2016;10:819-828. [PMID: 26903052 DOI: 10.1007/s12072-016-9705-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
16 Han B, Zhou L, Guan Q, da Roza G, Wang H, Du C. In Vitro Expansion and Characterization of Mesenchymal Stromal Cells from Peritoneal Dialysis Effluent in a Human Protein Medium. Stem Cells Int 2018;2018:5868745. [PMID: 30402111 DOI: 10.1155/2018/5868745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kim G, Shim KY, Baik SK. Diagnostic Accuracy of Hepatic Vein Arrival Time Performed with Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis. Gut Liver 2017;11:93-101. [PMID: 27538445 DOI: 10.5009/gnl16031] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
18 López-Beas J, Guadix JA, Clares B, Soriano-Ruiz JL, Zugaza JL, Gálvez-Martín P. An overview of international regulatory frameworks for mesenchymal stromal cell-based medicinal products: From laboratory to patient. Med Res Rev 2020;40:1315-34. [PMID: 32017179 DOI: 10.1002/med.21659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kim G, Kang SH, Kim MY, Baik SK. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS One. 2017;12:e0186990. [PMID: 29065187 DOI: 10.1371/journal.pone.0186990] [Cited by in Crossref: 97] [Cited by in F6Publishing: 105] [Article Influence: 19.4] [Reference Citation Analysis]
20 Luo YH, Chen J, Xiao EH, Li QY, Luo YM. Zebularine Promotes Hepatic Differentiation of Rabbit Bone Marrow Mesenchymal Stem Cells by Interfering with p38 MAPK Signaling. Stem Cells Int 2018;2018:9612512. [PMID: 30405726 DOI: 10.1155/2018/9612512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Nicolas CT, Wang Y, Nyberg SL. Cell therapy in chronic liver disease. Curr Opin Gastroenterol. 2016;32:189-194. [PMID: 26950359 DOI: 10.1097/mog.0000000000000262] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
22 Suk KT, Kim MY, Jeong SW, Jang JY, Jang YO, Baik SK. Impact of Bacterial Translocation on Hepatopulmonary Syndrome: A Prospective Observational Study. Dig Dis Sci 2018;63:248-56. [DOI: 10.1007/s10620-017-4868-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
23 Zhang Y, Li S, Wang G, Peng Y, Zhang Q, Li H, Zhang J, Wang G, Yi S, Chen X, Xiang AP, Yang Y, Chen G. Mesenchymal stem cells for treatment of steroid-resistant acute rejection after liver transplantation. Liver Research 2017;1:140-5. [DOI: 10.1016/j.livres.2017.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
24 Rhee KJ, Lee JI, Eom YW. Mesenchymal Stem Cell-Mediated Effects of Tumor Support or Suppression. Int J Mol Sci 2015;16:30015-33. [PMID: 26694366 DOI: 10.3390/ijms161226215] [Cited by in Crossref: 101] [Cited by in F6Publishing: 103] [Article Influence: 14.4] [Reference Citation Analysis]
25 Jang YO, Cho MY, Yun CO, Baik SK, Park KS, Cha SK, Chang SJ, Kim MY, Lim YL, Kwon SO. Effect of Function-Enhanced Mesenchymal Stem Cells Infected With Decorin-Expressing Adenovirus on Hepatic Fibrosis. Stem Cells Transl Med. 2016;5:1247-1256. [PMID: 27365486 DOI: 10.5966/sctm.2015-0323] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
26 Kang SH, Kim MY, Eom YW, Baik SK. Mesenchymal Stem Cells for the Treatment of Liver Disease: Present and Perspectives. Gut Liver 2020;14:306-15. [PMID: 31581387 DOI: 10.5009/gnl18412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
27 Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK, Park H, Hwang SG, Kim DJ, Lee BS, Lee SH, Kim HS, Jang JY, Lee CH, Kim BS, Jang YO, Cho MY, Jung ES, Kim YM, Bae SH, Baik SK. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology. 2016;64:2185-2197. [PMID: 27339398 DOI: 10.1002/hep.28693] [Cited by in Crossref: 103] [Cited by in F6Publishing: 108] [Article Influence: 17.2] [Reference Citation Analysis]
28 Kim G, Kim MY, Baik SK. Transient elastography versus hepatic venous pressure gradient for diagnosing portal hypertension: a systematic review and meta-analysis. Clin Mol Hepatol 2017;23:34-41. [PMID: 28263953 DOI: 10.3350/cmh.2016.0059] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
29 Williams P, Klersy C, Karki C, Bennett D, Rodríguez AM, Ciccocioppo R. Mesenchymal Stem Cell Therapy Awareness, Knowledge, and Use for the Treatment of Fistulizing Crohn’s Disease: An International Survey Among Gastroenterologists and Colorectal Surgeons. Adv Ther. [DOI: 10.1007/s12325-022-02113-5] [Reference Citation Analysis]
30 Lim YL, Kim MY, Jang YO, Baik SK, Kwon SO. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study. Gut Liver 2017;11:702-10. [PMID: 28651304 DOI: 10.5009/gnl16478] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
31 Kim G, Huh JH, Lee KJ, Kim MY, Shim KY, Baik SK. Relative Adrenal Insufficiency in Patients with Cirrhosis: A Systematic Review and Meta-Analysis. Dig Dis Sci 2017;62:1067-79. [DOI: 10.1007/s10620-017-4471-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
32 Eom YW, Yoon Y, Baik SK. Mesenchymal stem cell therapy for liver disease: current status and future perspectives. Curr Opin Gastroenterol 2021;37:216-23. [PMID: 33769377 DOI: 10.1097/MOG.0000000000000724] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Gan J, Wang Y, Zhou X. Stem cell transplantation for the treatment of patients with type 1 diabetes mellitus: A meta-analysis. Exp Ther Med 2018;16:4479-92. [PMID: 30542397 DOI: 10.3892/etm.2018.6769] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
34 Nowakowski A, Andrzejewska A, Boltze J, Nitzsche F, Cui LL, Jolkkonen J, Walczak P, Lukomska B, Janowski M. Translation, but not transfection limits clinically relevant, exogenous mRNA based induction of alpha-4 integrin expression on human mesenchymal stem cells. Sci Rep 2017;7:1103. [PMID: 28439079 DOI: 10.1038/s41598-017-01304-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
35 Kweon M, Kim JY, Jun JH, Kim GJ. Research Trends in the Efficacy of Stem Cell Therapy for Hepatic Diseases Based on MicroRNA Profiling. Int J Mol Sci 2020;22:E239. [PMID: 33383629 DOI: 10.3390/ijms22010239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Yao P. Stem cell based therapies for liver diseases: Current status and perspectives. Shijie Huaren Xiaohua Zazhi 2017; 25(1): 17-22 [DOI: 10.11569/wcjd.v25.i1.17] [Reference Citation Analysis]
37 Gorodetsky R, Aicher WK. Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies. Int J Mol Sci 2021;22:5302. [PMID: 34069909 DOI: 10.3390/ijms22105302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Lee CW, Chen YF, Wu HH, Lee OK. Historical Perspectives and Advances in Mesenchymal Stem Cell Research for the Treatment of Liver Diseases. Gastroenterology. 2018;154:46-56. [PMID: 29107021 DOI: 10.1053/j.gastro.2017.09.049] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]